Loading
A phase 3 trial of Elranatamab, Daratumumab, Lenalidomide in multiple myeloma, run by Pfizer, now recruiting.
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant is a phase 3 interventional study registered as NCT05623020 by Pfizer, with 1116 participants planned, started 2022-11-10 and due to reach its primary completion in 2030-10-18. Interventions recorded: Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Elranatamab, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Elranatamab, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Elranatamab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Pfizer (incl. Seagen).
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/